International Nazi Hunter Discusses Campaign To Find Surviving War Criminals

LOS ANGELES (CBSLA.com) — An international Nazi hunter who has dedicated his life to finding justice for the millions of Jews killed in the Holocaust was in Los Angeles Monday to discuss a newly launched campaign in Germany that will help locate war criminals.

“We’re talking about some of the biggest murderers in human history,” said Dr. Efraim Zuroff.

Zuroff, the chief Nazi hunter for the Los Angeles-based Simon Wiesenthal Center, talked about “Operation Last Chance”—a campaign that urges Germans to provide information on the whereabouts of any surviving Nazi war criminals.

“We started the campaign to focus on the people who served in the death camps, as well as in the Einsatzgruppen, the special mobile killing units,” he said.

Zuroff said of those 6,000, only 120 are still alive, but he believes younger generations have an obligation to hold criminals accountable.

“Old age should not afford protection for people who committed such heinous crimes. Just because a mass murderer reaches the age of 90 doesn’t turn them into a righteous Gentile,” he said.

Renee Firestone, 89, and her family were sent to Auschwitz, where she said her mother was gassed and her sister was tortured.

“I feel like justice should be done. (My sister) was used as a guinea pig for medical experiments and then she was shot,” she said.

Over the years, Zuroff said the Simon Wiesenthal Center has turned over more than 100 suspects to local prosecutors.

Right now, they are waiting for legal action for some of their most wanted, including Michael Karkoc, a suspected SS commandant who is accused of lying his way into the U.S. and is now living in Minnesota, and Hans Lipschis, who was believed to be an SS guard at Auschwitz.

RELATED STORY:

LA-Based Simon Wiesenthal Center Calls On Justice Department To Investigate Suspected Nazi War Criminal

blog comments powered by Disqus jQuery(document).ready(function($){ Gravatar.profile_cb = function( h, d ) { WPGroHo.syncProfileData( h, d );}; Gravatar.my_hash = WPGroHo.my_hash; Gravatar.init( 'body', '#wp-admin-bar-my-account' ); });if ( 'object' === typeof wpcom_mobile_user_agent_info ) {wpcom_mobile_user_agent_info.init();var mobileStatsQueryString = "";if( false !== wpcom_mobile_user_agent_info.matchedPlatformName )mobileStatsQueryString += "&x_" + 'mobile_platforms' + '=' + wpcom_mobile_user_agent_info.matchedPlatformName;if( false !== wpcom_mobile_user_agent_info.matchedUserAgentName )mobileStatsQueryString += "&x_" + 'mobile_devices' + '=' + wpcom_mobile_user_agent_info.matchedUserAgentName;if( wpcom_mobile_user_agent_info.isIPad() )mobileStatsQueryString += "&x_" + 'ipad_views' + '=' + 'views';if( "" != mobileStatsQueryString ) {new Image().src = document.location.protocol + '//stats.wordpress.com/g.gif?v=wpcom-no-pv' + mobileStatsQueryString + '&baba=' + Math.random();}}

View the original article here

Archbold, Ellis in the medals in international track cycling

The Australians fought back on the second day of the International Track Cycling Series in Adelaide last night.

The home team shut the New Zealanders off the podium in the sprints while Timaru’s Shane Archbold had to be content with second place in the omnium on countback and Lauren Ellis took bronze in the women’s omnium.

The BikeNZ contingent are competing in five days of UCI Tier One competition in Adelaide which carries qualifying points for upcoming World Cup events, which in turn qualify riders and teams for the World Championships.

Olympic sprint medallist Shane Perkins (AUS) edged Matt Archibald and Eddie Dawkins in qualifying for the sprint in 10.155s in a chilly Adelaide Super-Drome and was then unmatched in the elimination series, accounting for compatriot Peter Lewis in two straight rides in the final.

Archibald (Invercargill) was the best of the Kiwis after winning his first round over Wang Shengwei (CHN), Jacob Schmid (AUS) in the second round and Mitchell Bullen (AUS) in the quarterfinal. He lost out to Lewis 2-0 in the semifinal and to Nathan Hart in the ride-off for bronze.

Dawkins (Invercargill), who won the keirin on the first day, finished fifth when he won the ride-off for the minors after losing to Perkins in a closely fought quarterfinal, while Ethan Mitchell lost to Lewis in the same round.

Dunedin’s Katie Schofield missed out in the repechage for a place in the quarterfinals in the women’s sprint.

Archbold, who is competing on the road this year with UCI Pro Continental team An Post Sean Kelly in Europe, had a slender two point lead in the omnium after the first day to Australian Olympic gold medallist Alexander Edmondson.

The Australian drew level after finishing second in the 4000m individual pursuit with Archbold fourth in 4:32.130 and Southland’s Pieter Bulling seventh in 4:39.763.
Edmondson finished fourth, one spot ahead of Archbold with Bulling sixth in the 10km scratch race.

Archbold finished third in the final event, the 1000m time trial in 1:05.498 one place ahead of Edmondson to leave the pair level on 18 points but the Australian was given the top honours on countback.
Bulling was sixth in the time trial to finish sixth overall.

London Olympian Lauren Ellis finished third in the women’s omnium won by Australian Isabella King who dominated the competition.

Hamilton’s Jaime Nielsen won the individual pursuit in 3:40.957 ahead of King and Ellis (3:46.721) but the Australian fought back to win the scratch race with Ellis sixth and Nielsen sixth.

King took out the 500m time trial in 37.280 from Nielsen (37.495) with Ellis fourth in 37.838.

The Australian finished on seven points on the low point system to with China’s Xiaojuan Diao second on 18, Ellis third on 21 and Nielsen fifth on 25.

The five day competition reverts back to sprints and keirin competition in two sessions today.

View the original article here

Great Interest At International Headache Meeting On ElectroCore's Research Into The Treatment Of Cluster Headache

Main Category: Headache / Migraine
Article Date: 12 Jul 2013 - 2:00 PDT Current ratings for:
Great Interest At International Headache Meeting On ElectroCore's Research Into The Treatment Of Cluster Headache

There was great interest at the recent International Headache Congress in Boston in a poster on the results of an open label trial on non-invasive vagus nerve stimulation for the treatment of cluster headache. The trial sponsored by electroCore, one of the world leaders in the rapidly expanding field of electroceuticals, is part of the most comprehensive clinical trial programs in headache presently running.

The poster, authored by Drs. Peter Goadsby, Alex Nesbitt and Juana Marin reviewed their cohort of cluster headache patients who were successfully treated by nVNS over the past year.

electroCore's presentation in Boston represented a subset of the data it previously presented on at the INS (International Neuromodulation Society) 11th World Congress in Berlin, which illustrated that nVNS may have meaningful clinical benefits, both in offering relief from acute cluster headaches as well as reducing the frequency of attacks.

The poster reported on an open-label trial run by the Royal Free London NHS Foundation Trust at two sites in the UK and Ireland and which included data from 21 patients, five of whom were followed for twelve months. It concluded that nVNS, as delivered by electroCore's hand-held, home-use gammaCore device, appeared to be effective, safe and well-tolerated and useful for both acute and preventive treatment strategies of cluster headaches.

It further found that nVNS should be considered before surgically invasive neuro-stimulation, while the authors concluded that the data strongly supported the need for additional randomised studies of nVNS.

electroCore is conducting four randomized clinical trials, 2 of which are being conducted under an US, Investigational Device Exemption (IDE) for both migraine and cluster headaches.

Headaches are widely regarded as the world's most common debilitating neurological disorder, with cluster headaches considered to be one of the most painful - if not the most painful of all - headache conditions.

Cluster headaches are normally treated with a combination of oxygen, various drugs as well as surgically invasive neuro-stimulation. Oxygen presents portability issues, however, while high doses of certain medication are contraindicated or may have unacceptable side effects while any invasive surgery can require the use of anaesthetics and have a range of possible complications.

All the patients who took part in the trial recommended electroCore's non-invasive vagus nerve stimulation to other sufferers.

In the United States, only one product has been approved by the FDA for the treatment of acute cluster headaches. No products have been formally approved for reduction of cluster attacks.

Article adapted by Medical News Today from original press release. Click 'references' tab above for source.
Visit our headache / migraine section for the latest news on this subject.

The research showed that on average, 47 per cent of the treated attacks were terminated within 15 minutes.

There was also a reduction in the use of concomitant therapies, such as hi-flow oxygen and injectable triptans, which patients previously relied on.

The research showed that nVNS is also useful for preventive treatment. On average, the number of attacks within a 24 hour period was cut in half.

The trial detailed in this release was funded by the electroceutical healthcare company electroCore Medical LLC, a leader in its field. ElectroCore has discovered a novel technology which delivers very small, proprietary electrical signals to stimulate particular fibres in the vagus nerve which is believed to cause the release of inhibitory neurotransmitters in the brain stem, including GABA, serotonin and norepinephirine. These are believed to play a pivotal role in a wide range of conditions, including migraine and headache.

ElectroCore’s gammaCore has regulatory approval in the European Union, South Africa, India, New Zealand, Australia, Colombia and Malaysia for the acute and/or prophylactic treatment of migraine, cluster headache and medication overuse headache, as well as in Canada for the treatment and prevention of cluster headache and for the treatment of migraines. The product is currently being launched through healthcare professionals in Canada, Germany, UK, and other parts of Europe. GammaCore is not approved for use in the United States, and is being studied under an Investigational exemption for both migraine and cluster headaches.

ElectroCore

Please use one of the following formats to cite this article in your essay, paper or report:

MLA

ElectroCore. "Great Interest At International Headache Meeting On ElectroCore's Research Into The Treatment Of Cluster Headache." Medical News Today. MediLexicon, Intl., 12 Jul. 2013. Web.
12 Jul. 2013. APA

Please note: If no author information is provided, the source is cited instead.

'Great Interest At International Headache Meeting On ElectroCore's Research Into The Treatment Of Cluster Headache'

Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.

If you write about specific medications or operations, please do not name health care professionals by name.

All opinions are moderated before being included (to stop spam)

Contact Our News Editors

For any corrections of factual information, or to contact the editors please use our feedback form.

Please send any medical news or health news press releases to:

Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.

View the original article here